1. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

A549 cell

" in MedChemExpress (MCE) Product Catalog:

456

Inhibitors & Agonists

1

Fluorescent Dye

11

Peptides

1

Inhibitory Antibodies

104

Natural
Products

5

Isotope-Labeled Compounds

6

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-147027

    PARP Caspase Apoptosis Cancer
    PARP-1-IN-2 (compound 11g) is a potent and BBB-penetrated PARP1 inhibitor, with an IC50 of 149 nM. PARP1-IN-2 shows significantly potent anti-proliferative activity against Human lung adenocarcinoma epithelial cell line A549. PARP1-IN-2 can induce A549 cells apoptosis .
    PARP-1-IN-2
  • HY-145363

    Integrin Cancer
    Sulodexide (pIC50 = 8.2 nM) selectively binds to the αvβ5 integrin in K562 and A549 cell lines and exhibits a significant inhibitory effect .
    αvβ5 integrin-IN-1
  • HY-146105

    Apoptosis MDM-2/p53 MMP Bcl-2 Family Reactive Oxygen Species Cancer
    Anticancer agent 65 (compound 4c) shows excellent activity in cancer cell lines, especially A549 cells, with an IC50 of 1.07 μM. Anticancer agent 65 induces S-phase arrest in A549 cells and increases the expression level of p53 and p21. Anticancer agent 65 causes apoptosis, ROS generation and collapse of MMP in A549 cells .
    Anticancer agent 65
  • HY-145314

    Integrin Cancer
    TC113 is a c(RGDyK)-Based conjugate of Gemcitabine (GEM). TC113 could be internalized by A549 cells through integrin αvβ3. TC113 shows potent antiproliferative properties against WM266.4 and A549 cells .
    TC113
  • HY-170568

    Microtubule/Tubulin Apoptosis Cancer
    Tubulin polymerization-IN-73 (Compound 37) is an inhibitor for microtubule polymerization with an IC50 of 1.8 μM. Tubulin polymerization-IN-73 arrests the cell cycle at G2/M phase, induces apoptosis in A549 cell, inhibits the proliferation of A549 WT and A549/T resistant cell with IC50 of 0.023 μM and 0.057 μM. Tubulin polymerization-IN-73 exhibits antitumor efficacy in mouse model .
    Tubulin polymerization-IN-73
  • HY-156453

    PAK Apoptosis Cancer
    PAK4-IN-3(compound 27e) is aPAK4inhibitor, with theIC50of 10 nM.PAK4-IN-3shows antiproliferative activity against A549 cells with anIC50value of 0.61μM, and inducesapoptosisof A549 cells in a concentration-dependent manner and blocked the cell cycle at phase G0/G1 .
    PAK4-IN-3
  • HY-146274

    c-Met/HGFR Apoptosis Cancer
    c-Met-IN-10 (compound 26a) is a highly potent c-Met kinase inhibitor with an IC50 value of 16 nM. c-Met-IN-10 has inhibitory activity against cancer cells A549, H460 and HT-29 with IC50s of 0.56 ~ 1.59 μM. c-Met-IN-10 suppresses the colony formation on HT-29 cells, induces HT-29 and A549 cells apoptosis, and inhibits A549 cells motility. c-Met-IN-10 can be used for researching anticancer .
    c-Met-IN-10
  • HY-155396

    PROTACs HDAC Cancer
    PRO-HD1 is a PROTAC HDAC6 degrader. PRO-HD1 degrades HDAC6 in A549 cells, and inhibits proliferation of Jurkat cells (IC50: 5.8 μM) .
    PRO-HD1
  • HY-161891

    EGFR Akt Cancer
    EGFR/Akt-IN-1 (compound 17) is a potent inhibitor of EGFR/Akt, with the IC50s of 12.89 μM and 10.88 μM in A549 cells, respectively. EGFR/Akt-IN-1 arrestes the cell cycle at the S phase .
    EGFR/Akt-IN-1
  • HY-158019

    DNA/RNA Synthesis Cancer
    Anticancer agent 196 (compound 1) shows cell cytotoxicity with IC50  values of  7.69 µM and  54.2 µM for HL-60 cells and A549 cells, respectively. Anticancer agent 196 can induce DNA damage .
    Anticancer agent 196
  • HY-N11912

    Biochemical Assay Reagents Cancer
    Soladulcoside A is a steroidal glycoside and antineoplastic agent that can be obtained from the whole plant of Solanum nigrum. Soladulcoside A can inhibit A549 cells and has the potential to study cancers such as non-small cell lung cancer (NSCLC) .
    Soladulcoside A
  • HY-158020

    DNA/RNA Synthesis Cancer
    Anticancer agent 197 (compound 2b) shows cell cytotoxicity with IC50  values of  10.03 µM and  73.54 µM for HL-60 cells and A549 cells, respectively. Anticancer agent 197 can induce DNA damage .
    Anticancer agent 197
  • HY-N10201

    Endogenous Metabolite Cancer
    Cytoglobosin C, a cytochalasan derivative, shows potent cytotoxicity against both SGC-7901 and A549 cell lines (IC50<10 μM) .
    Cytoglobosin C
  • HY-162885

    Proteasome JAK STAT Interleukin Related Cancer
    YSY01A is a proteasome inhibitor that can suppress cancer cell survival by inducing apoptosis (Apoptosis). Its IC50 values are 51.0 nM for HEK293T, 9.2 nM for A549, 5.2 nM for MCF-7, 8.9 nM for MGC-803, and 35.4 nM for PC-3M cells. Additionally, YSY01A eliminates constitutive STAT3 signaling by downregulating gp130 and JAK2 in human A549 lung cancer cells. YSY01A holds promise for research in the field of cancer therapy .
    YSY01A
  • HY-168607

    TGF-beta/Smad Cancer
    ALK5-IN-83 (compound 13b) is a ALK5 inhibitor with the IC50 of 0.13 μM. ALK5-IN-83 inhibits TGF-β1-induced Smad2 phosphorylation and cell motility in A549 cells .
    ALK5-IN-83
  • HY-75564

    Endogenous Metabolite Cancer
    Cyclo(Ala-Gly), a metabolite of a mangrove endophytic fungus, Penicillium thomi, exhibits cytotoxicity against A549, HepG2 and HT29 cells. The IC50 values range from 9.5 to 18.1 μM .
    Cyclo(Ala-Gly)
  • HY-144394

    Apoptosis c-Met/HGFR Cancer
    Antitumor agent-45 (Compound 21) could induce and stimulate A549 cells apoptosis in G0/G1 and G2/M phase. Antitumor agent-45 (Compound 21) inhibits c-Met expression to regulate the growth of tumor cells .
    Antitumor agent-45
  • HY-131344

    mTOR Autophagy Cancer
    mTOR inhibitor-8 is an mTOR inhibitor and autophagy inducer. mTOR inhibitor-8 inhibits the activity of mTOR via FKBP12 and induces autophagy of A549 human lung cancer cells .
    mTOR inhibitor-8
  • HY-149840

    Apoptosis Cancer
    Antitumor agent-113 shows cytotoxic effects on A549 cells with IC50 value of 46.60 μM and induces apoptosis. Antitumor agent-113 can be used in non-small cell lung cancer study .
    Antitumor agent-113
  • HY-147030

    PARP Cancer
    PARP1-IN-8 (compound 11c) is a potent and BBB-penetrated PARP1 inhibitor, with an IC50 of 97 nM. PARP1-IN-8 shows significantly potent anti-proliferative activity against Human lung adenocarcinoma epithelial cell line A549 .
    PARP1-IN-8
  • HY-146319

    Macrophage migration inhibitory factor (MIF) Metabolic Disease Inflammation/Immunology Cancer
    MIF-IN-6 (compound 2d) is a potent macrophage migration inhibitory factor (MIF) inhibitor with an IC50 of 1.4 μM and a Ki value of 0.96 μM, respectively. MIF-IN-6 attenuates MIF-induced ERK phosphorylation and inhibits proliferation of A549 cells .
    MIF-IN-6
  • HY-163692

    Microtubule/Tubulin Apoptosis Cancer
    Tubulin polymerization-IN-64 (Compound 8a) is an inhibitor for tubulin polymerization by occupying the colchicine binding site of tubulin, with IC50 of 6.9 μM. Tubulin polymerization-IN-64 inhibits proliferations of cancer cells A549, HeLa, HCT116 and HT-29, with IC50s of 2.42, 10.33, 6.28, 5.33 μM, respectively. Tubulin polymerization-IN-64 arrests cell cycle at G2/M phase, induces apoptosis in A549 .
    Tubulin polymerization-IN-64
  • HY-147882

    Bacterial Infection
    Anti-MRSA agent 6 (compound 3q6) is a potent anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) agent. Anti-MRSA agent 6 shows low cytoxicity for MCF-7, A549 cells .
    Anti-MRSA agent 6
  • HY-158429

    PROTACs Cytochrome P450 Cancer
    PROTAC CYP1B1 degrader-2 (compound PV2) is a von Hippel-Landau (VHL) E3 ligase-based CYP1B1 degrader with the DC50 of 1.0 nM at 24 h in A549/Taxol cells. PROTAC CYP1B1 degrader-2 inhibits growth, migration, and invasion of A549/Taxol cell(Sturcture Note:(Blue: VHL ligand (HY-112078), Black: linker (HY-W007700), Pink: CYP1B1 ligand (HY-159006) .
    PROTAC CYP1B1 degrader-2
  • HY-129765

    Reactive Oxygen Species Cancer
    Thiobenzanilide 63T (63T) is a small molecule that selectively induces cancer cell death in a caspase-independent pathway. Thiobenzanilide 63T induces reactive oxygen species and lipid peroxidation. Thiobenzanilide 63T demonstrates strong cytotoxic activity against a lung-derived cancer cell line. Thiobenzanilide 63T decreases the expression of heme oxygenase (HO-1) in A549 cells .
    Thiobenzanilide 63T
  • HY-N7980

    NF-κB Cancer
    Rubipodanone A, a naphthohydroquinone dimer, shows cytotoxicity against A549, BEL-7402, HeLa, HepG2, SGC-7901 and U251 cells. Rubipodanone A also shows obvious activating effect at 20 and 40 μM for NF-κB .
    Rubipodanone A
  • HY-115941

    HDAC Microtubule/Tubulin Apoptosis Cancer
    HDAC-IN-9 is a potent and selective tubulin and HDAC dual inhibitor. HDAC-IN-9 inhibits the invasion and migration of A549 cells. HDAC-IN-9 shows potent antitumor and antiangiogenic effect in vitro and in vivo .
    HDAC-IN-9
  • HY-115983

    CD47 Apoptosis Cancer
    DMUP is a potent CD47-SIRPα axis inhibitor. DMUP induces apoptosis and increases the macrophage phagocytosis in A549 cells. DMUP decreases the expression of CD47 and SIRPα protein. DMUP shows antitumor activity .
    DMUP
  • HY-142945

    Ras Cancer
    KRAS G12C inhibitor 43 (compound 59) is a potent KRAS G12C inhibitor. KRAS G12C inhibitor 43 shows antimigration and anti-proliferative activity with IC50s of 0.001-1 µM, >1 µM, >1 µM for H358, A549, HCC cells ,respectively .
    KRAS G12C inhibitor 43
  • HY-145963

    GLUT Cancer
    DRB18 is a potent pan-class GLUT inhibitor. DRB18 alters energy-related metabolism in A549 cells by changing the abundance of metabolites in glucose-related pathways. DRB18 can eventually lead to G1/S phase arrest and increase oxidative stress and necrotic cell death. DRB18 has anti-tumor activity .
    DRB18
  • HY-152100

    Autophagy Cancer
    CUR5g is a potent autophagy inhibitor. CUR5g selectively inhibits autophagosome degradation in cancer cells by blocking autophagosome-lysosome fusion. CUR5g blocks the recruitment of STX17 to autophagosomes via a UVRAG-dependent mechanism, resulting in the inability of autophagosomes to fuse with lysosomes. CUR5g improves the anticancer effect of Cisplatin (HY-17394) against A549 cells both in vitro and in vivo .
    CUR5g
  • HY-143466

    FAK ULK AMPK Apoptosis Autophagy Cancer
    ULK1-IN-2 (compound 3s) is a potent ULK1 inhibitor. ULK1-IN-2 shows highest cytotoxic effect against cancer cell lines, with IC50 of 1.94 μM in A549. ULK1-IN-2 can induce apoptosis and simultaneously block autophagy, and can be used to study NSCLC (Non-small cell lung cancer) .
    ULK1-IN-2
  • HY-151295

    DNA/RNA Synthesis Cancer
    Antitumor agent-75 is a novel potent antitumor agent. Antitumor agent-75 has cytotoxic effects on cancer and normal human cell lines. Antitumor agent-75 shows a highly selective cytotoxic effect against human lung adenocarcinoma (cell line A549) when combined with Antitumor agent-74 (HY-151292), the IC50 value of 2.8 μM. Antitumor agent-75 can be used for the research of cancer .
    Antitumor agent-75
  • HY-162808

    DNA/RNA Synthesis Cancer
    GTSE1-IN-1 (compound Y18) is an orally active GTSE1 inhibitor with anticancer activity. GTSE1-IN-1 significantly inhibits cancer cell proliferation by inhibiting the transcription and expression of GTSE1, causing DNA damage and persistently inducing cell cycle arrest and cell senescence. In addition, GTSE1-IN-1 significantly inhibits the adhesion, migration and invasion of colorectal cancer HCT116 cells and non-small cell lung cancer A549 cells in vitro .
    GTSE1-IN-1
  • HY-115947

    Drug Derivative Cancer
    Anticancer agent 33 (compound 3), a Squamocin and Bullatacin derivative, is a potent anticancer agent. Anticancer agent 33 shows high potency to inhibit 4T1 breast cancer cell line (A549, HeLa, HepG2 and MCF-7 cells) growth with IC50s of 1.9-5.4 µM .
    Anticancer agent 33
  • HY-146061

    Ras Cancer
    KRAS G12C inhibitor 48 (compound 6e) is a potent KRAS G12C inhibitor with an IC50 of 639.91 nM. KRAS G12C inhibitor 48 (0-50 µM) shows anti-proliferative activity with IC50s of 0.796, 6.33, 16.14 µM for H358, H23, A549 cells, respectively .
    KRAS G12C inhibitor 48
  • HY-155231

    Elastase Cancer
    Neutrophil elastase inhibitor 4 (compound 4f) is a competitive human neutrophil elastase (HNE) inhibitor (IC50: 42.30 nM, Ki: 8.04 nM). Neutrophil elastase inhibitor 4 induces T47D cell apoptosis. Neutrophil elastase inhibitor 4 inhibits cell proliferation with IC50s of 21.25, 34.17, 29.93, 99.11 nM for T47D, RPMI 8226, A549, and HSF cells .
    Neutrophil elastase inhibitor 4
  • HY-N10113

    Muconomycin B

    Apoptosis Arenavirus Fungal Antibiotic Reactive Oxygen Species Infection Cancer
    Verrucarin J (Muconomycin B) is a metabolite of the Myrothecium fungus family. Verrucarin J generates reactive oxygen species (ROS) and induces apoptosis of cancer cell lines, such as A549, HCT 116 and SW-620 cells. Verrucarin J shows activities against Candida albicans and Mucor miehei. Verrucarin J inhibits arenavirus Junin (JUNV) yield with an IC50 of 1.2 ng/mL .
    Verrucarin J
  • HY-147538

    Apoptosis Cancer
    Antitumor agent-64 (Compound 8d) is a diosgenin derivative. Antitumor agent-64 exhibits potent cytotoxic activity against A549 cell line. Antitumor agent-64 induces A549 cells apoptosis via the mitochondria-related pathway .
    Antitumor agent-64
  • HY-N10208

    Endogenous Metabolite Cancer
    Aspericin C is a pyran derivative found in the marine-derived fungus Rhizopus sp. 2-PDA-61. Aspericin C shows cytotoxic activities against P388, A549, HL-60, and BEL-7420 cell lines (IC50=14.6, 7.1, 61.4, and 24.2 μM, respectively) .
    Aspericin C
  • HY-145290

    Topoisomerase Apoptosis Cancer
    CPT-Se3, a selenoproagent of Camptothecin (CPT), shows improved potency in killing cancer cells and inhibiting tumor growth. CPT–Se3 decreases the GSH/GSSG ratio and total thiols, elevates the ROS level in Hep G2 cells, and eventually induces apoptosis of cancer cells. CPT-Se3 shows cytotoxicity against HeLa, Hep G2, A549, and SMMC-7721 cells (IC50= 2.19-4.7 μM) .
    CPT-Se3
  • HY-145291

    Topoisomerase Apoptosis Cancer
    CPT-Se4, a selenoproagent of Camptothecin (CPT), shows improved potency in killing cancer cells and inhibiting tumor growth. CPT-Se4 decreases the GSH/GSSG ratio and total thiols, elevates the ROS level in Hep G2 cells, and eventually induces apoptosis of cancer cells. CPT-Se4 shows cytotoxicity against HeLa, Hep G2, A549, and SMMC-7721 cells (IC50= 2.54-6.4 μM) .
    CPT-Se4
  • HY-153259

    PARP Cancer
    TNKS1/2-IN-2 (Compound 21) is a potent and selective tankyrases inhibitor. TNKS1/2-IN-2 exhibits IC50 values of 4 nM and 63 nM against TNK1 and TNK2 in the enzymatic assay, respectively. TNKS1/2-IN-2 inhibits proliferation of A549 and H292 cell lines with IC50 values of 39.5 nM and 12.8 nM, respectively. TNKS1/2-IN-2 can be used for the research of cancer .
    TNKS1/2-IN-2
  • HY-149890

    Apoptosis Cancer
    Anticancer agent 130 (compound 8d) is an anticancer agent that can significantly induce apoptosis in A549 cells .
    Anticancer agent 130
  • HY-P1935

    Biochemical Assay Reagents Cancer
    Cyclo(Ala-Pro) is an anticancer agent that is toxic to cancer cells such as A549, HCT-116 and HepG2 .
    Cyclo(Ala-​Pro)
  • HY-168251

    PROTACs Epigenetic Reader Domain Cancer
    PROTAC BRM/BRG1 degrader-3 (compound 304) is a PROTACs-based BRM/BRG1 degrader with a DC50 of less than 1 nM for BRM degradation in SW1573 cells and a DC50 of greater than 1 nM for BRG1 degradation in SW1573 cells. PROTAC BRM/BRG1 degrader-3 has anti-tumor activity and anti-proliferative activity against A549 cells (IC50=0.6 nM). (Structure Note: PINK, Target protein ligand (HY-168252); Blue, E3 (HY-168253); Black, linker (HY-69260)).
    PROTAC BRM/BRG1 degrader-3
  • HY-139425

    Biochemical Assay Reagents Cancer
    Cyclo(Pro-Ala) is an anticancer agent that has toxic to cancer cells such as A549, HCT-116, and HepG2 .
    Cyclo(Pro-Ala)
  • HY-159820

    Others Cancer
    Veonetinib (example 3) is a potent inhibitor of tyrosine kinase, with the IC50 of 0.1 μM and 0.4 μM in A549 cells and LOVO cells, respectively .
    Veonetinib
  • HY-12757
    YHO-13177
    2 Publications Verification

    BCRP Cancer
    YHO-13177, a acrylonitrile derivative, is an orally active, potent and specific inhibitor of breast cancer resistance protein (BCRP) and ABCG2 with an IC50 value of 10 nM. YHO-13177 potentiates the cytotoxicity of SN-38 in HCT116 and A549 cells that express BCRP. YHO-13177 combined with Irinotecan (HY-16562) significantly suppresses the tumor growth in an HCT116/BCRP xenograft model .
    YHO-13177
  • HY-160927

    Drug Derivative Cancer
    Docosahexaenoyl Serinol (Compound 1) inhibits proliferation of lung cancaer cells A549, with 77.4% inhibition rate at 3 μM .
    Docosahexaenoyl Serinol

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: